Bevacizumab for Neovascular Age-related Macular Degeneration
- Sponsor
- Peking University People's Hospital
- Study ID
- NCT01306591
- Status
- Completed
Conditions
- Exudative Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab 1 — DRUGBevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
- Bevacizumab — DRUGBevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
Study Details
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.
Key Dates
- First listed
- Mar 2, 2011
- Start date
- Jan 31, 2008
- Status verified
- Dec 2010
- Primary completion
- Jun 30, 2010
- Completion
- Dec 31, 2010
Study Design
- Enrollment
- 210 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Bevacizumab 1
- Active Comparator: Bevacizumab 2
Primary Outcome Measure
EDTRS visual acuity score [ Time Frame: 0week(baseline), 6week, 12week, 18week, 24week, 30week, 36week, 42week, 48week ]